Organization
Cancer Research Advocates Forum , London, United Kingdom
1 abstract
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,